Interactions: Administer cautiously to opioid dependent patients including newborns of mother's dependant or those suspected of having received large doses and observe for signs of acute withdrawal.
Pregnancy and Lactation: Prenoxad should be used with caution in pregnancy. The neonate must also be monitored for signs of opioid withdrawal. Naloxone may be administered during the second stage of labour to correct any respiratory depression due opioid analgesics. It is not known whether Naloxone is excreted in human milk therefore use with caution in breastfeeding mothers.
Undesirable Effects: Common side effects include nausea, vomiting, dizziness, headache, ventricular tachycardia, hypotension and hypertension. Less common side effects: Tremor, sweating, arrhythmia, bradycardia, diarrhoea, dry mouth, hyperventilation, inflammation. Seizure tension, allergic reactions, anaphylactic shock, fibrillation, cardiac arrest, erythema multiforme, fever, dyspnoea, runny nose, sneezing and yawning. Piloerection, weakness, shivering.
Product Licence Number: PL 12064/0125 Product Licence Holder: Aurum Pharmaceuticals Ltd, Bampton Road, Harold Hill, Romford, Essex RM3 8UGBasic NHS Price: £18.00 Legal Category: POM. Date of Preparation: April 2013 For more details contact: Aurum Pharmaceuticals Hubert Road, Brentwood, Essex CM14 4LZ +44(0)1277-266600 Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Martindale Pharma Tel. +44(0)1277-266600 Fax +44(0)1708-382739 e-mail firstname.lastname@example.org For further information visit http://www.martindalepharma.co.uk For further information on Prenoxad Injection please contact Martindale Pharma on +44(0)800-0287933 or our Medical Information Team on +44(0)1708-382145 or via email@example.com. Media contacts: Martindale Pharma Michael Clark Tel: +44(0)1277-235300 M:Communications Mary Clark / Amber Bielecka / Hollie Vile Tel : +44(0)207-920-2361 SOURCE Martindale Pharma